Skip to main content
Premium Trial:

Request an Annual Quote

Ronald Lindsay, Dmitry Samarsky, Beckman Coulter



HistoRx last week announced the appointment of Ronald Lindsay, the former chief scientific officer and vice president of research and development at diaDexus, to its board of directors.

Lindsay has held key leadership roles at Millenium Pharmaceuticals and Regeneron Pharmaceuticals. He currently heads a biopharmaceutical-consulting firm, Milestone Consulting and is a non-executive director at Sequenom and ArQule.

Dmitry Samarsky has recently been named director of technology development at Dharmacon.

Previously, Samarsky was with Invitrogen, where he formulated partnership models and helped develop platform solutions for the drug discovery process, according to Dhamacon. Before that, he was with Sequitur, which was acquired by Invitrogen in late 2003. Samarsky holds a PhD from the University of Massachusetts, Amherst.


Beckman Coulter last week introduced a new monocloncal antibody for natural killer cell research, the company said.

The IOTest Anti-IRp60-PE monoclonal antibody enables the identification of an inhibitory protein present on NK and dendritic cells. According to Beckman, this PE-conjugated antibody is the first Anti-IRp60 reagent on the market, and as Beckman's other universal cytometry reagents, works on all of the company's instrument platforms. The pre-formulated, standardized antibody is provided in 50-test vials, is ready to use, adapted for lysing procedures with a wash, and may be used in multi-color applications, Beckman said.